Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Plasma metabolic markers and their application for differentiating benign and malignant ovarian tumors

A technology for metabolic markers, ovarian malignant tumors, applied in the direction of material separation, analysis of materials, instruments, etc., can solve the problem of lack of biomarkers, distinguish borderline ovarian tumors and malignant ovarian tumors, unsatisfactory specificity and sensitivity, etc. question

Active Publication Date: 2022-06-17
FUDAN UNIV
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the specificity and sensitivity of the current clinically used indicators are not satisfactory, so it is necessary to develop new biomarkers or models for the diagnosis and early diagnosis of ovarian cancer
And there is currently no simple and convenient means to diagnose ovarian diseases (benign tumors, borderline tumors and malignant tumors), and there is no biomarker to distinguish borderline ovarian tumors from malignant ovarian tumors, so it is necessary to explore these two aspect biomarkers

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Plasma metabolic markers and their application for differentiating benign and malignant ovarian tumors
  • Plasma metabolic markers and their application for differentiating benign and malignant ovarian tumors
  • Plasma metabolic markers and their application for differentiating benign and malignant ovarian tumors

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] 1. Participants and study design

[0021] A total of 420 patients with primary ovarian cancer (OC), benign ovarian tumors, borderline ovarian tumors and normal donors were recruited. Urine and plasma samples from participants were collected between September 2016 and May 2018, and were between the ages of 14 and 84. The enrolled patients did not receive any radiotherapy or chemotherapy, nor did they suffer from metabolic diseases, including but not limited to liver disease, diabetes and kidney disease. In addition, patients taking drugs that were shown to alter metabolism were also excluded. All ovarian cancer patients in this study underwent surgery and the diagnosis was further confirmed by at least two pathologists. The discovery set of our project consisted of 326 samples (plasma and urine, respectively: 40 normal controls, 36 benign, 13 borderline, and 74 malignant. Of these, plasma and urine samples from 148 participants were paired). An external cohort (plasma...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Sensitivityaaaaaaaaaa
Sensitivityaaaaaaaaaa
Sensitivityaaaaaaaaaa
Login to View More

Abstract

The invention belongs to the technical field of biomedicine, and specifically relates to a plasma metabolic marker for distinguishing benign and malignant ovarian tumors and an application thereof. The present invention provides a new combination of plasma diagnostic markers for distinguishing benign and malignant (borderline + malignant) ovarian tumors, and can also be used to distinguish benign and early malignant ovarian tumors (borderline + malignant), with high accuracy and sensitivity High characteristics, the AUC of the training set reached 0.876, and the AUC of the verification set was 0.896. The AUC of the early diagnosis training set is 0.847, and the AUC of the verification set is 0.988, which is better than that of CA125 (AUC: training set: 0.733; verification set: 0.893). The marker combination belongs to plasma small molecule metabolites and has the advantage of being non-invasive.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to a plasma metabolic marker for distinguishing benign and malignant ovarian tumors and its application. Background technique [0002] Ovarian cancer (OC) is one of the deadliest cancers of gynecologic malignancies, with 294,414 new ovarian cancer cases and 184,799 ovarian cancer deaths worldwide. Due to the insidious onset and the lack of effective measures such as census and early diagnosis, 80% of women are already in the late stage at the time of diagnosis. Ovarian cancer survival is highly correlated with tumor stage. The 5-year survival rates for early-stage ovarian cancer and advanced-stage ovarian cancer differ significantly. The 5-year survival rate for patients with FIGO stage I is as high as 92%, while the 5-year survival rate for patients with FIGO stage IV is only 5%. Therefore, early diagnosis is an effective method to improve the prognosis of ovarian cancer. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): G01N30/02G01N30/06G01N30/34G01N30/86
CPCG01N30/02G01N30/06G01N30/34G01N30/8675
Inventor 刘小娜刘雷刘刚程玺陈丽华
Owner FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com